Abstract

BackgroundCarnitine palmitoyltransferase 1A (CPT1A) deficiency is a rare mitochondrial fatty acid oxidation (FAO) disorder that results in hypoketotic hypoglycemia and hepatic encephalopathy. It is caused by mutation in CPT1A. To date, only two symptomatic cases of CPT1A deficiency have been reported in China.Case presentationA newborn male, without any disease-related clinical manifestations, was diagnosed with CPT1A deficiency through newborn screening. Increased free carnitine levels and a significantly increased C0/(C16 + C18) ratio were detected by tandem mass spectrometry, and subsequently, mutations in CPT1A were found by gene sequence analysis. The patient was advised a low-fat, high-protein diet and followed up regularly. During three-years of follow-up since, the patient showed normal growth velocity and developmental milestones. Whole-exome sequence identified two mutations, c.2201 T > C (p.F734S) and c.1318G > A (p.A440T), in the patient. The c.2201 T > C mutation, which has been reported previously, was inherited from his father, while the c.1318G > A, a novel mutation, was inherited from his mother. The amino acid residues encoded by original sequences are highly conserved across different species. These mutations slightly altered the three-dimensional structure of the protein, as analyzed by molecular modeling, suggesting that they may be pathogenic.ConclusionThis is the first case of CPT1A deficiency detected through newborn screening based on diagnostic levels of free carnitine, in China. Three years follow-up suggested that early diagnosis and diet management may improve the prognosis in CPT1A patient. In addition, we identified a novel mutation c.1318G > A in CPT1A,and a possible unique to Chinese lineage mutation c.2201 T > C. Our findings have expanded the gene spectrum of this rare condition and provided a basis for family genetic counseling and prenatal diagnosis.

Highlights

  • Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a rare mitochondrial fatty acid oxidation (FAO) disorder that results in hypoketotic hypoglycemia and hepatic encephalopathy

  • This is the first case of CPT1A deficiency detected through newborn screening based on diagnostic levels of free carnitine, in China

  • Three years follow-up suggested that early diagnosis and diet management may improve the prognosis in CPT1A patient

Read more

Summary

Conclusion

We used neonatal screening using MS/MS to diagnose CPT1A deficiency in presymptomatic newborn. The early diagnosis and diet management improved the prognosis in our patient. We need to expand the scope of neonatal MS/MS screening in whole country, improve the speed of the test time, and prefect the feedback mechanism in the future. We identified a novel mutation c.1318G > A in CPT1A, which is probably disease-causing mutation, and c.2201. T > C mutation may be unique to Chinese lineage. Our finding has expanded the gene spectrum of this rare condition and provided a basis for genetic counseling of the family and prenatal diagnosis. Abbreviations CPT1A: Carnitine palmitoyltransferase 1A; FAO: fatty acid oxidation; MS/ MS: tandem mass spectrometry; MRM: mutiple reaction monitoring

Background
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call